RT Journal Article
T1 Sentinel Lymph Node Biopsy in Breast Cancer with Tc-99m-Tilmanocept: A Multicenter Study on Real-Life Use of a Novel Tracer
A1 Vidal-Sicart, Sergi
A1 Eugenia Rioja, Maria
A1 Prieto, Andrea
A1 Goni, Elena
A1 Gomez, Isabel
A1 Dolores Albala, Maria
A1 Lumbreras, Luis
A1 Fernanda Leon, Luisa
A1 Ramon Gomez, Jose
A1 Campos, Francisco
K1 breast cancer
K1 sentinel node
K1 tilmanocept
K1 lymphoscintigraphy
K1 axillary staging
K1 Lymphoscintigraphy
K1 Reproducibility
K1 Identification
K1 Spect/ct
K1 Metaanalysis
K1 Tilmanocept
K1 Accuracy
K1 Melanoma
K1 Receptor
AB Tc-99m-tilmanocept is a novel radiopharmaceutical for sentinel lymph node (SLN) biopsy in breast cancer. Our aim was to describe results with Tc-99m-tilmanocept in a heterogeneous group of breast cancer patients scheduled for SLN biopsy. Methods: Radiotracer preparation followed the manufacturer's indications. Local protocols for SLN detection within 9 participant centers were not changed for the entire duration of the study. In total, 344 patients with T1-T4, N0-N2 breast cancer (352 lesions) were included. Superficial (ntradermal or periareolar) or deep (peritumoral or intratumoral) injections were performed. The doses were adjusted depending on the scheduled time for surgery. Results: Lymphoscintigraphy was able to depict at least 1 SLN in 339 of 352 breast lesions (96.3%), and the intraoperative SLN detection rate reached 97.2%. On univariable analysis, SLN detection rates did not differ by age, clinical T or N stage, tumor location, histologic subtype, or prior neoadjuvant therapy. Lymphoscintigraphy showed higher SLN detection in patients with a normal weight (body mass index = 25), at 99.2% versus 94.6%, respectively (P = 0.031). The proportion of patients with preoperative lymphoscintigraphic detection or excised SLNs was higher with superficial than deep injections. Reinjected cases were significantly lower when superficial injection was chosen first (P
PB Soc nuclear medicine inc
SN 0161-5505
YR 2021
FD 2021-05-01
LK http://hdl.handle.net/10668/19204
UL http://hdl.handle.net/10668/19204
LA en
DS RISalud
RD Apr 18, 2025